Mouse Models of Retinitis Pigmentosa Mirror the Human Disease RP59 Pathobiology

Researchers have developed mouse models with DHDDS gene mutations that accurately reflect the retinal degeneration observed in human RP59, advancing understanding of the disease mechanisms and potential treatments.
Retinitis pigmentosa (RP) is a hereditary eye condition characterized by progressive retinal degeneration that ultimately leads to vision loss. This condition involves mutations in nearly 100 different genes, making it a complex and genetically diverse disease. Among these genes, one encodes the enzyme DHDDS, which plays a crucial role in protein glycosylation. Mutations in DHDDS cause a specific form of RP called RP59, which is inherited in a recessive pattern—meaning both copies of the gene must contain mutations for the disease to manifest.
To deepen the understanding of RP59 and to explore potential treatments, researchers at the University of Alabama at Birmingham, led by Dr. Steven Pittler, have developed novel mouse models carrying mutations in the mouse equivalent of the DHDDS gene. The initial model, identified as the K42E/K42E mutant, features mutations at amino acid position 42, where lysine (K) is replaced by glutamic acid (E). This particular mutation mirrors a common variant found in human RP59 patients.
Building on this, the team has now established two additional mouse models featuring mutations at a different site: T206A/K42E and T206A/T206A. The T206A mutation involves replacing threonine (T) at amino acid position 206 with alanine (A). At 12 months of age, both the T206A/K42E and T206A/T206A mice demonstrated retinal structural and functional changes similar to the earlier K42E/K42E model. These alterations include a reduction in inner nuclear layer thickness, decreased densities of bipolar and amacrine cells, and altered electrical responses of the retina, assessed through electroretinography. Notably, while the light-sensitive photoreceptor cells (a-wave) remained relatively intact, inner retinal layers (b-wave) showed significant decline, indicating inner retinal dysfunction.
These findings suggest that the T206A mutation causes retinal degeneration through mechanisms similar to the K42E mutation. Importantly, the T206A allele, although not yet observed in humans, appears to be pathogenic. This supports the idea that defective synaptic transmission between photoreceptors and bipolar cells—a critical component of visual signal processing—plays a central role in RP59 pathogenesis. Since bipolar cells transmit visual information from the retina to the optic nerve, their degeneration contributes to vision loss.
Dr. Pittler emphasizes that understanding these mutations enhances our knowledge of how genetic variants lead to retinal degeneration, potentially guiding the development of targeted therapies. The mouse models serve as vital tools for future research aimed at halting or reversing retinal damage associated with RP59.
Source: https://medicalxpress.com/news/2025-08-retinitis-pigmentosa-mouse-pathobiology-human.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Educational Strategies Drive Adoption of Lifestyle Medicine in Health Systems
A recent study reveals that targeted educational strategies—such as CME courses, certifications, and conferences—are key to integrating lifestyle medicine into healthcare systems, supporting clinician education and practice change.
Breakthrough in Cancer Treatment: Experimental Drug Advances to Human Clinical Trials
Innovative compounds targeting the RAS gene pathway have advanced to human trials, showing promise for more effective and safer cancer treatments by selectively inhibiting tumor growth mechanisms.
Using Multifocal Contact Lenses to Slow Eye Growth and Reduce Childhood Myopia
Innovative high-add multifocal contact lenses show promise in slowing eye growth and reducing myopia progression in children, according to recent studies highlighting biological mechanisms involved in eye development.
Exploring Verapamil's Potential to Slow Progression of Type 1 Diabetes
Recent research suggests that verapamil, a calcium channel blocker, could help slow the progression of type 1 diabetes by preserving beta-cell function. The Ver-A-T1D trial shows promising results, highlighting future potential therapies for this autoimmune disease.



